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Objectives
Analyze the various package leaflets on Artemisinin-
based combination therapy (ACT) marketed in Côte-
d’Ivoire.
Methods
Comparative study, conducted from June 1 to December
20, 2011 which included all package inserts for all ACT
registered and marketed in Côte-d’Ivoire. The inserts’
content was compared to that of European product
descriptions; our investigation focused particularly on
side effects.
Results
Regarding artemether-lumefantrine, all leaflets described
digestive disorders. As far as endocrinal and metabolic sys-
tems are concerned, appetite loss and anorexia were
described in 28,5% and 42,8% of leaflets. As far as skin and
annexes are concerned, we found: rash (100%), pruritus
(90%), slate-gray pigmentation (28%) and redness of the
face (14%). Finally, only notices of plasmocid® and coar-
tem® reported biological side effects. As regards the arte-
sunate-amodiaquine, blood effects were described:
agranulocytosis (60%), blood dyscrasia and leucopenia
(40%), hemolytic anemia (20%). At the gastrointestinal
level, were found nauseas, vomiting and diarrhea (80%),
hepatitis (60%), fatal hepatitis (20%). On the level of the
nervous system was mentioned peripheral neuropathy
(80%), the extra-pyramidal syndrome (20%). At the general
level, it was asthenia only found in the leaflet of camoquin
plus®.
Conclusion
Information of the laboratories differing from one speci-
alty to another for the same molecule, it would be
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